← Back to Search

Unknown

Intervention 1 for Epilepsy

Phase 1
Waitlist Available
Research Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 days

Summary

This trial is testing a new drug called OPC-214870 to help people with epilepsy who do not get better with current medications. The drug works by affecting certain brain pathways to reduce seizures.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Standardized Photosensitivity Range (SPR)
Secondary study objectives
Onset and duration of SPR

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Intervention 1Experimental Treatment2 Interventions
Single dose; up to 400 mg capsule; adaptive dosage determined by initial dosing from cohort 1.Potential for a matching placebo dose to be administered.
Group II: PlaceboPlacebo Group2 Interventions
Single dose; potential for a matching OPC-214870 dose to be administered.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
OPC-214870
2020
Completed Phase 1
~20

Find a Location

Who is running the clinical trial?

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor
264 Previous Clinical Trials
170,063 Total Patients Enrolled
~3 spots leftby Oct 2025